Show
Sort by
-
- Journal Article
- A2
- open access
Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation
-
Performance evaluation of RNA purification kits and blood collection tubes in the Extracellular RNA Quality Control (exRNAQC) study
-
- Journal Article
- A2
- open access
Exploration of neuroblastoma xenograft models for tumor extracellular RNA profiling in murine blood plasma
-
- Conference Paper
- C3
- open access
Exploration of neuroblastoma xenograft models for the analysis of tumoral cell-free RNA in murine blood plasma
-
Performance evaluation of RNA purification kits and blood collection tubes in the Extracellular RNA Quality Control (exRNAQC) study
-
- Conference Paper
- C3
- open access
Dramatic impact of blood collection tube and RNA purification method on extracellular RNA transcriptomes
-
Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA
(2023) -
- Journal Article
- A2
- open access
Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA
-
- Journal Article
- A1
- open access
Digital PCR-based evaluation of nucleic acid extraction kit performance for the co-purification of cell-free DNA and RNA
-
The Extracellular RNA Quality Control (exRNAQC) study (phase 1)
(2022) -
The Extracellular RNA Quality Control (exRNAQC) study (phase 2)
(2022) -
- Miscellaneous
- open access
Performance evaluation of RNA purification kits and blood collection tubes in the Extracellular RNA Quality Control (exRNAQC) study
-
Whole transcriptome profiling of liquid biopsies from tumor xenografted mouse models enables specific monitoring of tumor-derived RNA
-
Whole transcriptome profiling of liquid biopsies from tumor xenografted mouse models enables specific monitoring of tumor-derived RNA
-
Exploration of neuroblastoma xenograft models for tumor extracellular RNA profiling in murine blood plasma
(2022) -
- Journal Article
- A1
- open access
A G316A polymorphism in the ornithine decarboxylase gene promoter modulates MYCN-driven childhood neuroblastoma
-
Whole transcriptome profiling of liquid biopsies from tumor xenografted mouse models enables specific monitoring of tumor-derived RNA
-
Whole transcriptome profiling of liquid biopsies from tumor xenografted mouse models enables specific monitoring of tumor-derived RNA
-
Whole transcriptome profiling of liquid biopsies from tumor xenografted mouse models enables specific monitoring of tumor-derived RNA
-
- Journal Article
- A1
- open access
A recurrent and transesophageal echocardiography-associated outbreak of extended-spectrum β-lactamase-producing Enterobacter cloacae complex in cardiac surgery patients
-
- Journal Article
- A1
- open access
Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR
-
Nosocomial outbreak of extended-spectrum β-lactamase-producing Enterobacter cloacae among cardiothoracic surgical patients : causes and consequences
-
ALK positively regulates MYCN activity through repression of HBP1 expression
-
Whole transcriptome profiling of liquid biopsies from patient-derived xenograft (PDX) models
-
Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11
-
Pharmacological restoration of tumour suppressor protein p53 in neuroblastoma : seeking synergy and non-invasive biomarkers
-
Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium
-
Performance of the preanalytical check module of the Stago STA R Max2 mechanical endpoint detection analyzer for assessing the impact of hemolysis, lipemia, and icterus on aPTT and PT
-
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
-
The ornithine decarboxylase G316A promoter polymorphism impacts neuroblastoma clinical outcome and may identify patients particularly susceptible to polyamine inhibition
-
Longitudinal evaluation of murine serum microRNAs as biomarkers for neuroblastoma burden and therapeutic TP53 reactivation
-
Circulating microRNA biomarkers for metastatic neuroblastoma
-
Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays
-
Analytical and pre-analytical performance characteristics of a novel cartridge-type blood gas analyzer for point-of-care and laboratory testing
-
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex
-
Hepatitis E virus serology and PCR : does the methodology matter?
-
MicroRNA expression analysis using small RNA sequencing discovery and RT-qPCR-based validation
-
Analytical and diagnostic performance evaluation of the new Sysmex UF-5000 for automated urine sediment analysis
-
Identifying familial hypercholesterolemia in pediatric and adult patients : is screening relevant in a tertiary care setting?
-
Accelerating drug development for neuroblastoma - New drug development strategy : an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
-
Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis
-
A negative lactate dehydrogenase activity corrected after sample neuraminidase treatment
-
- Journal Article
- A1
- open access
Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay
-
- Journal Article
- A1
- open access
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
-
HBP1 is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex
-
The HBP1 tumour suppressor is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex
-
Evaluation of the role of germline RECQL variants in Belgian patients referred for genetic testing in the context of familial breast/ovarian cancer
-
- Journal Article
- A1
- open access
Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation
-
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers
-
- Journal Article
- A1
- open access
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
-
BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers
-
- Journal Article
- A1
- open access
Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples
-
The HBP1 tumor suppressor is an epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex
-
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex
-
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex
-
Identification of non-invasive biomarkers for treatment response in neuroblastoma by circulating miRNA profiling
-
The HBP1 tumour suppressor at multiple regulatory cross roads in neuroblastoma
-
Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment
-
Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment
-
Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment
-
- Journal Article
- A1
- open access
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers
-
Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment
-
- Miscellaneous
- open access
Oncogenetic testing for persons with hereditary endocrine cancer syndromes
-
The G2 micronucleus-assay for the analysis of in vitro chromosomal radiosensitivity in individuals carrying a BRCA1 mutation
-
Hepatitis E virus serology and PCR : does the methodology matter?
-
HBP1 downregulation through mutant ALK represents a novel mechanism for cooperative MYCN activation in neuroblastoma
-
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c. 1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
-
Synergistic combined molecular treatment targeting the HBP1 tumor suppressor gene in neuroblastoma
-
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
-
- Journal Article
- A1
- open access
Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
-
- Journal Article
- A1
- open access
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors
-
- Journal Article
- A1
- open access
Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma
-
- Journal Article
- A1
- open access
Identification of miRNAs contributing to neuroblastoma chemoresistance
-
- Miscellaneous
- open access
Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li-Fraumeni syndrome and Cowden syndrome
-
- Miscellaneous
- open access
Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2
-
The G2 micronucleus assay for the analysis of in vitro chromosomal radiosensitivity in individuals carrying a BRCA1 or BRCA2 mutation
-
Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma
-
Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma
-
Targeted analysis of TP53 pathway SNPs in neuroblastoma patients
-
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients
-
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients
-
- Journal Article
- A1
- open access
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
-
Clinical burden of hepatitis E infections in Belgium
-
- Journal Article
- A1
- open access
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients
-
Characterization of ALK driven molecular networks identifies perturbed RET and cholinergic signaling in neuroblastoma
-
Genetisch geïnspireerde toekomstperspectieven voor de therapie van het neuroblastoom
-
The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity
-
The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity
-
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma
-
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
-
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance
-
Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma
-
Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma
-
The G2-micronucleus assay for the detection of in vitro chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers
-
- Journal Article
- A1
- open access
Focal DNA copy number changes in neuroblastoma target MYCN regulated genes
-
- Journal Article
- A1
- open access
Effective Alu repeat based RT-qPCR normalization in cancer cell perturbation experiments
-
Identifying and validating DNA methylation biomarkers: the example of neuroblastoma
-
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
-
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
-
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers